The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of topotecan and cisplatin with sequential radiotherapy in elderly small cell lung cancer patients (Okayama Lung Cancer Study Group; OLCSG 0102).
 
Toshio Kubo
Honoraria - Kyowa Hakko Kirin; Shionogi; Taiho Pharmaceutical
 
Shingo Harita
No Relationships to Disclose
 
Toshiaki Okada
No Relationships to Disclose
 
Haruhito Kamei
No Relationships to Disclose
 
Shinobu Hosokawa
No Relationships to Disclose
 
Tadashi Maeda
No Relationships to Disclose
 
Toshiyuki Kozuki
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Roche Pharma AG; Sanofi; Taiho Pharmaceutical
 
Keiichi Fujiwara
No Relationships to Disclose
 
Katsuyuki Hotta
No Relationships to Disclose
 
Nagio Takigawa
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Pfizer; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Nihonkayaku (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Mitsune Tanimoto
No Relationships to Disclose
 
Katsuyuki Kiura
Honoraria - Chugai Pharma; Lilly Japan; Pfizer; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Lilly (Inst)